Published in J Clin Oncol on August 01, 1992
Effect of Aromatase Inhibitors on Bones and Genes | NCT00603967
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev (2008) 3.13
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol (2011) 2.57
Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. Cancer Res (2014) 1.65
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer (2010) 1.52
Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat (2008) 1.34
Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol (2012) 1.27
The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol (2011) 1.19
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer (1999) 1.14
Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms. Mol Endocrinol (2008) 1.13
pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Br J Cancer (1996) 1.11
Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer (2013) 1.09
Selected antioxidants and risk of hormone receptor-defined invasive breast cancers among postmenopausal women in the Women's Health Initiative Observational Study. Am J Clin Nutr (2008) 1.06
Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305. Breast Cancer Res Treat (2009) 1.05
EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. Int J Cancer (2009) 0.99
Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers. Breast Cancer Res (2008) 0.98
Melatonin: an inhibitor of breast cancer. Endocr Relat Cancer (2015) 0.96
Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer (2012) 0.96
Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers. Breast Cancer Res (2010) 0.96
Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer (1994) 0.93
Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol (2010) 0.92
Assessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione. J Nucl Med (2012) 0.92
Methylsulfonylmethane suppresses breast cancer growth by down-regulating STAT3 and STAT5b pathways. PLoS One (2012) 0.90
Markers of endocrine sensitivity. Breast Cancer Res (2008) 0.90
Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer (2015) 0.90
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. Br J Cancer (1999) 0.89
Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br J Cancer (2002) 0.89
Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease. Br J Cancer (2003) 0.89
Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol (2011) 0.89
Pathological characteristics of BRCA-associated breast cancers in Hispanics. Breast Cancer Res Treat (2011) 0.88
Estrogen receptor-alpha polymorphism in a Taiwanese clinical breast cancer population: a case-control study. Breast Cancer Res (2004) 0.88
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. J Cancer (2016) 0.87
Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alpha. BMC Cancer (2008) 0.87
The effect of genital and lower urinary tract symptoms on steroid receptor expression in women with genital prolapse. Int Urogynecol J (2010) 0.82
Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor. Mol Cancer (2010) 0.82
Sequential Metastatic Breast Cancer Chemotherapy: Should the Median be the Message? Front Public Health (2013) 0.82
Presence of exon 5-deleted oestrogen receptor in human breast cancer: functional analysis and clinical significance. Br J Cancer (1997) 0.82
Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. Br J Cancer (2002) 0.82
Role of the progesterone receptor (PR) in the regulation of inflammatory response pathways and aromatase in the breast. J Steroid Biochem Mol Biol (2006) 0.81
Biologic characteristics of premalignant breast disease. Cancer Biomark (2010) 0.81
Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res (2011) 0.81
Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. J Zhejiang Univ Sci B (2010) 0.81
A comparison of manual and automated methods of quantitation of oestrogen/progesterone receptor expression in breast carcinoma. J Clin Diagn Res (2015) 0.79
Mediation of Racial and Ethnic Disparities in Estrogen/Progesterone Receptor-Negative Breast Cancer by Socioeconomic Position and Reproductive Factors. Am J Epidemiol (2016) 0.78
Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. PLoS One (2015) 0.77
Steroid hormone receptors and their clinical significance in cancer. J Clin Pathol (1995) 0.75
Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer. Breast Cancer Res Treat (2016) 0.75
Role of traditional and new biomarkers in breast carcinogenesis. Ecancermedicalscience (2009) 0.75
Characterization and Clinical Implication of Th1/Th2/Th17 Cytokines Produced from Three-Dimensionally Cultured Tumor Tissues Resected from Breast Cancer Patients. Transl Oncol (2015) 0.75
MicroRNA regulation of progesterone receptor in breast cancer. Oncotarget (2017) 0.75
Examining the Relationship between Pre-Malignant Breast Lesions, Carcinogenesis and Tumor Evolution in the Mammary Epithelium Using an Agent-Based Model. PLoS One (2016) 0.75
Fibroblast growth factor signalling induces loss of progesterone receptor in breast cancer cells. Oncotarget (2016) 0.75
Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data. CMAJ Open (2017) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (1990) 11.92
Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis (2000) 11.44
Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature (1986) 11.35
The identification of genes with unique and essential functions in the development of the zebrafish, Danio rerio. Development (1996) 8.87
Functional domains of the human estrogen receptor. Cell (1987) 6.52
Localisation of the oestradiol-binding and putative DNA-binding domains of the human oestrogen receptor. EMBO J (1986) 6.08
Nuclear receptors enhance our understanding of transcription regulation. Trends Genet (1988) 5.95
Oestradiol induction of a glucocorticoid-responsive gene by a chimaeric receptor. Nature (1987) 5.47
Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis (1997) 5.13
Early clinical and laboratory indicators of acute dengue illness. J Infect Dis (1997) 5.00
Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA (1995) 4.88
Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci U S A (1985) 4.58
The chicken oestrogen receptor sequence: homology with v-erbA and the human oestrogen and glucocorticoid receptors. EMBO J (1986) 4.47
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst (1993) 4.45
The yeast UASG is a transcriptional enhancer in human HeLa cells in the presence of the GAL4 trans-activator. Cell (1988) 4.22
The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell (1988) 4.17
Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res (1977) 4.02
The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J (1992) 3.92
Screening for prostate cancer. Cochrane Database Syst Rev (2006) 3.46
Cathepsin D and prognosis in breast cancer. N Engl J Med (1990) 3.43
The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer (1980) 3.34
Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med (1989) 3.21
Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem (1978) 3.05
HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol (1989) 2.96
Genomic organization of the human oestrogen receptor gene. EMBO J (1988) 2.65
Fatty acid composition of erythrocytes and plasma triglyceride and cardiovascular risk in Asian diabetic patients. Lancet (1994) 2.65
Short course prednisolone for adhesive capsulitis (frozen shoulder or stiff painful shoulder): a randomised, double blind, placebo controlled trial. Ann Rheum Dis (2004) 2.54
Chemical generation of nitric oxide in the mouth from the enterosalivary circulation of dietary nitrate. Nat Med (1995) 2.50
A new method of estimating prevalence of injecting drug use in an urban population: results from a Scottish city. Int J Epidemiol (1991) 2.49
The 40K activity of one gram of potassium. Phys Med Biol (1997) 2.48
Effect of tumour necrosis factor on cultured human melanoma cells. Nature (1975) 2.46
Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology (1978) 2.42
Partial purification of a serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1976) 2.42
A superfamily of potentially oncogenic hormone receptors. Nature (1987) 2.40
The optimal timing of mastectomy: low tide or high tide? Ann Intern Med (1991) 2.40
Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem (1990) 2.37
A high carbohydrate leguminous fibre diet improves all aspects of diabetic control. Lancet (1981) 2.35
Studies on the mechanism of steroid hormone regulation of synthesis of specific proteins. Recent Prog Horm Res (1969) 2.31
Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science (1975) 2.29
Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst (1991) 2.29
Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology (1978) 2.25
Corticosteroid injections for shoulder pain. Cochrane Database Syst Rev (2003) 2.23
HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens (2002) 2.18
Mortality among injecting drug users: a critical reappraisal. J Epidemiol Community Health (1993) 2.17
Corynebacterium parvum as the priming agent in the production of tumor necrosis factor in the mouse. J Natl Cancer Inst (1977) 2.15
HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res (1990) 2.14
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol (1987) 2.12
Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy (2013) 2.10
Current status of estrogen and progesterone receptors in breast cancer. Cancer (1977) 2.10
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol (1992) 2.05
'Curing' empty follicle syndrome. Hum Reprod (1997) 2.01
Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors. Cancer (1990) 2.00
Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst (1993) 1.99
Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol (1978) 1.99
Scatchard plots: common errors in correction and interpretation. Steroids (1975) 1.98
Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst (1993) 1.95
Monoclonal antibodies against three major glycoproteins of varicella-zoster virus. Infect Immun (1983) 1.95
Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working? J Infect (2000) 1.94
Evaluation of a postal screening questionnaire to identify the physically disabled. Int Rehabil Med (1980) 1.94
Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res (1991) 1.92
Immunology and biochemistry of Regan isoenzyme of alkaline phosphatase in human cancer. Nature (1968) 1.89
Steroid receptor analyses of nine human breast cancer cell lines. Cancer Res (1978) 1.87
Pseudo-Gaucher cells in the bone marrow of a patient with Hodgkin's disease. Am J Clin Pathol (1987) 1.86
Triazolam as a substance of abuse among injecting drug users. Br J Addict (1992) 1.86
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol (1984) 1.84
Auditory sensitivity of the monkey. Science (1966) 1.81
Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med (1983) 1.79
PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochem Biophys Res Commun (1993) 1.79
Paradoxical response to nebulised salbutamol in wheezy infants, assessed by partial expiratory flow-volume curves. Thorax (1987) 1.77
Knowledge of and attitude toward patient confidentiality within three family medicine teaching units. Acad Med (1998) 1.77
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol (1993) 1.76
The transcriptional activation function located in the hormone-binding domain of the human oestrogen receptor is not encoded in a single exon. EMBO J (1989) 1.75
DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer (1988) 1.75
Rapid diagnosis of dengue viremia by reverse transcriptase-polymerase chain reaction using 3'-noncoding region universal primers. Am J Trop Med Hyg (1997) 1.75
Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat (1992) 1.74
MCF-7; a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors. Steroids (1975) 1.72
Screening for disability in the inner city. J Epidemiol Community Health (1981) 1.72
Human serum beta-glucuronidase; its measurement and some of its properties. Clin Chim Acta (1967) 1.71
Retracted Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer (2010) 1.69
The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol (1993) 1.69
Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr (2001) 1.67
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol (1994) 1.67
Current status of estrogen receptors in human breast cancer. Cancer (1975) 1.66
Nuclear mechanisms of estrogen action. Effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing. J Biol Chem (1978) 1.66
Poland anomaly with a limb body wall disruption defect: case report and review. Am J Med Genet (1992) 1.66
The alpha1-fetoprotein locus is activated by a nuclear receptor of the Drosophila FTZ-F1 family. Mol Cell Biol (1996) 1.66
Mechanisms of hemorrhage in dengue without circulatory collapse. Am J Trop Med Hyg (2001) 1.65
Molecular evolution of dengue type 2 virus in Thailand. Am J Trop Med Hyg (1998) 1.63
Immunopathologic mechanisms of dengue hemorrhagic fever and dengue shock syndrome. Arch Virol Suppl (1994) 1.61
Prevalence of malnutrition on admission to four hospitals in England. The Malnutrition Prevalence Group. Clin Nutr (2000) 1.56
Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer (1993) 1.54
Pre-operative education for hip or knee replacement. Cochrane Database Syst Rev (2004) 1.53
Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer. Cancer Res (1986) 1.53
Multiple estrogen receptor assays in human breast cancer. Cancer Res (1983) 1.52
Dose response evaluation of adriamycin in human neoplasia. Cancer (1977) 1.51
Improved sensitivity in the measurement of estrogen receptor in human breast cancer. J Clin Endocrinol Metab (1973) 1.51
Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res (1993) 1.51